New pfizer drug takes on Hard-to-Treat cancers

NCT ID NCT04606446

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 24, 2026

Summary

This study tests a new drug called PF-07248144, alone or combined with other cancer treatments, in people with advanced breast, prostate, or lung cancers that have not responded to standard therapy. The trial aims to find safe doses and check for early signs of tumor shrinkage. About 320 participants will take part across multiple locations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Aichi Cancer Center Hospital
RECRUITING

Nagoya, Aichi-ken, 464-8681, Japan
Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Beijing Cancer hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Cancer Research South Australia
RECRUITING

Adelaide, South Australia, 5000, Australia
Cedars Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Cedars-Sinai Cancer at Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Chris O'Brien Lifehouse
TERMINATED

Camperdown, New South Wales, 2050, Australia
Holy Cross Hospital
TERMINATED

Fort Lauderdale, Florida, 33308, United States
HonorHealth
TERMINATED

Scottsdale, Arizona, 85258, United States
Jilin Province Tumor Hospital
RECRUITING

Changchun, Jilin, 130000, China
Jilin Province Tumor Hospital
RECRUITING

Changchun, Jilin, 132000, China
Kanagawa cancer center
RECRUITING

Yokohama, Kanagawa, 2418515, Japan
Kyungpook National University Chilgok Hospital
RECRUITING

Daegu, Taegu-kwangyǒkshi, 41404, South Korea
MD Anderson
RECRUITING

Sugar Land, Texas, 77478, United States
MD Anderson League City
RECRUITING

League City, Texas, 77573, United States
MD Anderson The Woodlands
RECRUITING

Conroe, Texas, 77384, United States
MD Anderson West Houston
RECRUITING

Houston, Texas, 77079, United States
NEXT Oncology
RECRUITING

San Antonio, Texas, 78229, United States
National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
Peter MacCallum Cancer Centre
RECRUITING

Melbourne, Victoria, 3000, Australia
Royal Melbourne Hospital
RECRUITING

Parkville, Victoria, 3050, Australia
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
SUN Yat-Sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
Samsung Medical Center
RECRUITING

Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
Seoul National University Bundang Hospital
RECRUITING

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, Seoul-teukbyeolsi [seoul], 03080, South Korea
Severance Hospital, Yonsei University Health System
RECRUITING

Seoul, Seoul-teukbyeolsi [seoul], 03722, South Korea
Smilow Cancer Hospital Phase 1 Unit
RECRUITING

New Haven, Connecticut, 06511, United States
Smilow Cancer Hospital at Yale - New Haven
RECRUITING

New Haven, Connecticut, 06510, United States
St. Elizabeth Healthcare
RECRUITING

Edgewood, Kentucky, 41017, United States
St. John of God Subiaco Hospital
RECRUITING

Subiaco, Western Australia, 6008, Australia
Swedish Cancer Institute
RECRUITING

Seattle, Washington, 98104, United States
Swedish Medical Center
RECRUITING

Seattle, Washington, 98122, United States
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, Shaanxi, 710061, China
The University of Texas M. D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
U.T. MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
UCSF Medical Center at Mission Bay
RECRUITING

San Francisco, California, 94158, United States
University Medical Center, lnc.:DBA University of Louisville Hospital
RECRUITING

Louisville, Kentucky, 40202, United States
University of Louisville
RECRUITING

Louisville, Kentucky, 40202, United States
UofL Health Brown Cancer Center
RECRUITING

Louisville, Kentucky, 40202, United States
Western Health-Sunshine & Footscray Hospitals
RECRUITING

St Albans, Victoria, 3021, Australia
Yale University
RECRUITING

New Haven, Connecticut, 06511, United States
Yale-New Haven Hospital- Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PF-07248144 (a KAT6 inhibitor drug)

What this could lead to

If successful, this could lead to a new treatment option for people with advanced breast, prostate, or lung cancers that have stopped responding to standard therapies.

What could go wrong

This is an early-phase trial (Phase 1/2a) focused mainly on safety and dosing, so it is not yet known if the drug will effectively shrink tumors or improve survival. Side effects are still being identified.

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma estrogen-receptor positive breast cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED OR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER LOCALLY ADVANCED OR METASTATIC ER+ HER2- BREAST CANCER LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER